thymidine has been researched along with 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haraguchi, K; Sumino, M; Tanaka, H | 1 |
| Haraguchi, K; Sumino, M; Takeda, S; Tanaka, H | 1 |
| Baba, M; Cheng, YC; Tanaka, H; Wang, X | 1 |
| Aubry, A; Guha, M; Hawthorne, D; Liu, G; Liu, Y; Shen, JX; Yuan, L; Zhao, Y | 1 |
| Alexander, AJ; Hooker, TF; Tomasella, FP; Zhang, L | 1 |
| Bertz, R; Boué, F; Chan, HP; Chang, I; Cotte, L; Dellamonica, P; Grasela, DM; Hanna, GJ; Hwang, C; Molina, JM; Raffi, F; Urata, Y; Yazdanpanah, Y; Zhu, L | 1 |
| Deminie, C; Dicker, I; Hanna, GJ; Hwang, C; Krystal, M; Lataillade, M; Li, Z; Minassian, B; Nowicka-Sans, B; Olds, W; Protack, T; Sun, Y; Terry, B | 1 |
| Flint, OP; Wang, F | 1 |
| Aoki, M; Desai, DV; Kodama, EN; Maeda, K; Mitsuya, H; Nakata, H | 1 |
| Bertz, R; Cheng, YC; Grasela, D; Hanna, GJ; Hawthorne, D; Hwang, C; Matsuda, T; Paintsil, E; Sevinsky, H; Urata, Y | 1 |
| Dara, H; Frank, S; Marc, D; Mausumee, G; Michael, G; Sanderson, TP; Shawn, C; Soleil, PM; Zhao, Y | 1 |
| Benkovics, T; Beutner, GL; Bultman, M; Kronenthal, DR; Nye, J; Ortiz, A; Sfouggatakis, C; Shi, Z | 1 |
| Aubry, AF; Garrison-Borowski, P; Schuster, A; Shen, JX; Yuan, L | 1 |
| Ba, S; Gottlieb, GS; Leong, SS; Oakes, MK; Parker, KM; Raugi, DN; Seydi, M; Smith, RA; Sow, PS; Wu, VH | 1 |
| Avihingsanon, A; Echevarría, J; Gupta, SK; Hanna, GJ; Joshi, SR; Lataillade, M; Lombaard, J; McComsey, GA; Orrell, C; Osiyemi, O; Ray, N; Santoscoy, M; Stock, DA | 1 |
3 trial(s) available for thymidine and 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine
| Article | Year |
|---|---|
Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects.
Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Placebos; Reverse Transcriptase Inhibitors; RNA, Viral; Thymidine; Viral Load; Young Adult | 2013 |
Randomized, placebo-controlled single-ascending-dose study to evaluate the safety, tolerability and pharmacokinetics of the HIV nucleoside reverse transcriptase inhibitor, BMS-986001, in healthy subjects.
Topics: Adult; Anti-HIV Agents; Dose-Response Relationship, Drug; Fasting; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Single-Blind Method; Thymidine; Young Adult | 2014 |
Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial.
Topics: Adolescent; Adult; Bone and Bones; Bone Density; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Thymidine; Young Adult | 2016 |
12 other study(ies) available for thymidine and 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine
| Article | Year |
|---|---|
Nucleophilic substitution at the 4'-position of nucleosides: new access to a promising anti-HIV agent 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine.
Topics: Anti-HIV Agents; Indicators and Reagents; Nucleosides; Stavudine; Structure-Activity Relationship; Thymidine | 2006 |
An alternative method suitable for a large scale synthesis of 4'-ethynyl-2',3'-didehydro-3'-deoxythymidine.
Topics: Combinatorial Chemistry Techniques; Stavudine; Thymidine | 2004 |
Retention of metabolites of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel anti-human immunodeficiency virus type 1 thymidine analog, in cells.
Topics: Anti-HIV Agents; Biological Transport; Cell Line; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dipyridamole; Humans; Multidrug Resistance-Associated Proteins; Phosphodiesterase Inhibitors; Phosphorylation; Stavudine; Thymidine; Zidovudine | 2009 |
Improved ruggedness of an ion-pairing liquid chromatography/tandem mass spectrometry assay for the quantitative analysis of the triphosphate metabolite of a nucleoside reverse transcriptase inhibitor in peripheral blood mononuclear cells.
Topics: Animals; Chromatography, High Pressure Liquid; Drug Stability; Hydrogen-Ion Concentration; Ions; Leukocytes, Mononuclear; Macaca fascicularis; Nucleotides; Organic Chemicals; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Thymidine | 2013 |
Comparison of supercritical fluid chromatography and reverse phase liquid chromatography for the impurity profiling of the antiretroviral drugs lamivudine/BMS-986001/efavirenz in a combination tablet.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chromatography, Liquid; Chromatography, Supercritical Fluid; Cyclopropanes; Drug Combinations; Hydrogen-Ion Concentration; Lamivudine; Reverse Transcriptase Inhibitors; Tablets; Temperature; Thymidine | 2013 |
In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.
Topics: Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Mutation; Reverse Transcriptase Inhibitors; Thymidine | 2013 |
BMS-986001, an HIV nucleoside reverse transcriptase inhibitor, does not degrade mitochondrial DNA in long-term primary cultures of cells isolated from human kidney, muscle, and adipose tissue.
Topics: Adenine; Adipocytes; DNA Fragmentation; DNA, Mitochondrial; Epithelial Cells; Humans; Kidney Tubules, Proximal; Mitochondria; Muscle Fibers, Skeletal; Organophosphonates; Primary Cell Culture; Reverse Transcriptase Inhibitors; Stavudine; Structure-Activity Relationship; Tenofovir; Thymidine | 2013 |
Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.
Topics: Adenine; Amino Acid Sequence; Anti-HIV Agents; Deoxyadenosines; Deoxycytidine; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; HIV-1; Human Immunodeficiency Virus Proteins; Humans; Lamivudine; Molecular Sequence Data; Molecular Structure; Organophosphonates; Tenofovir; Thymidine | 2014 |
Nonclinical Safety Profile of BMS-986001, a Nucleoside Transcriptase Inhibitor for Combination Retroviral Therapy.
Topics: Anemia, Macrocytic; Animals; Anti-HIV Agents; Biotransformation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drugs, Investigational; Erythropoiesis; Female; Half-Life; HIV-1; Macaca fascicularis; Male; Mitochondria; Purpura, Thrombocytopenic; Random Allocation; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Survival Analysis; Thymidine; Toxicity Tests, Chronic; Toxicokinetics | 2014 |
Scalable Synthesis of the Potent HIV Inhibitor BMS-986001 by Non-Enzymatic Dynamic Kinetic Asymmetric Transformation (DYKAT).
Topics: Anti-HIV Agents; Catalysis; Levamisole; Stereoisomerism; Thymidine | 2015 |
Dried blood spot analysis without dilution: Application to the LC-MS/MS determination of BMS-986001 in rat dried blood spot.
Topics: Animals; Anti-HIV Agents; Chromatography, Liquid; Female; Limit of Detection; Pregnancy; Rats; Tandem Mass Spectrometry; Thymidine | 2015 |
The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.
Topics: Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Models, Molecular; Mutagenesis, Site-Directed; Protein Conformation; Reverse Transcriptase Inhibitors; Stavudine; Thymidine | 2015 |